A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Inclusion Criteria: * An informed consent document signed and dated by the subject. * Male or female individuals who are 18 to 65 years of age, inclusive * Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg * Heterosexually active male participants and their female partners of childbearing potential must agree to use 2 effective birth control methods for the duration of the study and for 90 days after the last dose of study intervention. * Females of childbearing potential must agree to use 2 effective birth control methods for the duration of the study and for 30 days after the last dose of study intervention. Exclusion Criteria: * Clinically relevant evidence or history of illness or disease * Clinically relevant risk factors for cardiovascular abnormalities * Pregnant or nursing females * History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection * Infection with HIV, HBV, HCV, or SARS CoV 2 * Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy) * Before the first dose of study intervention, participant has received any vaccine, an investigational agent or biological product within 28 days or 5 times the terminal half-life (t½), whichever is longer * A positive urine drug screen at Screening or Day -1 * Current tobacco smokers or use of tobacco within 3 months prior to Screening * History of regular alcohol consumption